London (CNN) – The Oxford / AstraZeneca vaccine will reduce the transmission of the virus, by simply reducing the severity of the illness, the United Kingdom investigators suggest.
The test case of positive PCR tests decreased approximately at the dose dose limit, following the preliminary results of Oxford University investigators which have not been revised in pairs.
MIRA: The most important thing is that there are more vacancies and we can move to covid-19, dice expert
In its analysis, published as a pre-publication on March, it also reflects the spacing of the dose and estimates a good efficacy after a single injection of the Oxford-AstraZeneca vaccine.
This is where the Oxford / AstraZeneca vaccine will be reduced.
The studio does not mediate the transmission directly, for example, scans contacts that were infected by the volunteers of the studio. However, investigators are collecting regular nasal hypoxia from participating participants who receive the Oxford / AstraZeneca vaccine and find that the test case of positive PCRs is reduced at the metastatic dose of the vaccine dose. After a single dose, the positive test dose is reduced by 67%.
MIRA: What is the most effective vaccine against covid-19?
“If the transmission studies were not included in the analysis, there would be a number of volunteers who would attend all seminars at the Reino Unido studio, independently of the syndicates, to allow the evaluation of the general impact of the vaccine on the risk of infection and, therefore, a substitute for potential future transmission », the authors write.
If the vaccine simply hiccups the more severe infections, the positivity of PCR does not change, the authors argue in the analysis of the pre-publication. “A general positivity assessment of PCR is appropriate for evaluation and there is a reduction in the burden of infection.”
Vaccine vaccines against the coronavirus are mainly involved in the prevention of covid-19 cases. Previously, she had public data suggesting that vacancies should be avoided by people transmitting the infection to others.
Hacen missing dates to confirm that the Oxford / AstraZeneca vaccine reduces transmission
In statements by the Science Media Center (SMC) of the United Kingdom, Helen Fletcher, Professor of Immunology at the School of Hygiene and Tropical Medicine of London, said that the dates of the study “suggest the possibility that the vaccine could have an impact on the transmission, but more necessary series to confirm this ».
El Dr. Doug Brown, executive president of the British Society of Immunology, told the SMC that the study “insinuates that the Oxford / AstraZeneca vaccine can be effective in preventing people from transmitting the virus”.
Addition: “Well, this is a very well-known newsletter, we need more dates,” Brown Brown said, whether the Oxford / AstraZeneca car will reduce transmission, ».
MIRA: Asia produces Oxford / AstraZeneca vaccine against covid-19 in Argentina
Spacing the dose of the vaccine
The Oxford / AstraZeneca vaccine showed 66.7% efficacy in the treatment of syphilis from the second week since the second injection, said Oxford University investigators.
The new analysis aggregates new test sites and a month of new data on the mix, based on the previous results announced by AstraZeneca that its vacancy showed an estimated efficiency of 70.4%.
Without embarrassment, the latest investigations also suggest that the vaccine may offer a protective protection after a single injection.
El estudio estima una eficacia del 76% has the highest doses of the one dose. It is based on a sub-group of 88 symptomatic infections, dividing by different ways between the groups of vaccines and placebo between 22 and 90 days after the vaccination. The study also found relatively stable levels of anticipation during this time period, “with a minimum reduction for day 90”.
MIRA: El Dr. Huerta received the second dose of Moderna. Here is his Experience
Podría haber burgemeester eficacia si se espacian las dosis
In addition, the authors suggest that a mayor may have an office with more space for him. Between the ages of 18 and 55, the vaccination rate increase increases as the time between injections is less than six weeks. At 12 o’clock, more information is needed to know what its statistics are different from.
In addition, the hallazgos can reforce the decision of the United Kingdom to recommend spacing the dose up to 12 weeks of difference, according to a statement by Oxford Vaccine Trial’s lead researcher and co-author of the article, Andrew Pollard.
“This is a positive note, it shows that a single dose of this vaccine generates good levels of immunity and that this protection does not decrease in the courtroom,” said Brown, of the British Society of Immunology.
“In terms of immunology, this hall is not in vain, and we know that some other vacancies configure more immunization when the dose is more distributed. Although more information is required to confirm these halls for the groups of mayor edad, in general, this new investigation should bring tranquility to the decision of the United Kingdom to reduce the dose of this vaccine by 12 weeks of difference ».
A similar data is available on the retrieval of the second dose of the Pfizer / BioNTech vaccine 12 weeks after the first dose, the Dr. Gillies O’Bryan-Tear, former President of Policies and Communications of the Faculty of Pharmacology in comments to the SMC. Pero, agregó, «la Mayoría de los comentaristas stán de acuordo en que es probable que suceda lo mismo con esa vacuna y, de hecho, con otras vacunas de dos dosis».
The authors advised that the assays should not be designed initially to evaluate the efficacy at dose intervals, but the data “surgeon should start with the logistics of conducting clinical trials on a large scale in a pandemic setting”.
The main analysis is based on 332 symptomatic infections that occur among more than 17,000 volunteers from the United Kingdom, Brazil and South Africa more than two weeks after their second dose.
AstraZeneca announced the last step in completing the enrollment in its Phase 3 enactment in the United States, which will serve as the “principal base” for the company’s eventual application to the United States Medicines and Food Administration.
The vaccine has been authorized in various countries, such as the United Kingdom and India, but it is possible that the authorization not to go to the United States is final in March as soon as possible, according to Moncef Slaoui of Operation Warp Speed.